radotinib

Radotinib is an orally available, second-generation small molecule tyrosine kinase inhibitor primarily indicated for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), especially in patients who are resistant or intolerant to other Bcr-Abl tyrosine kinase inhibitors such as imatinib. Its mechanism of action involves selective inhibition of the Bcr-Abl fusion protein by binding to its ATP-binding site, thereby blocking its kinase activity and downstream signaling pathways that promote cancer cell proliferation. Radotinib also inhibits platelet-derived growth factor receptor (PDGFR) and has some activity against other kinases at higher concentrations. The drug was developed by Ilyang Pharmaceutical and is co-marketed by Daewoong Pharmaceutical in South Korea[1][3][4][5][6].

Brand names

Supect

Other names

radotinib hydrochloride